The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
A | Alimentary tract and metabolism | |
2
|
A05 | Bile and liver therapy | |
3
|
A05B | Liver therapy, lipotropics | |
4
|
A05BA | Liver therapy | |
5
|
A05BA11 |
| Active Ingredient |
|---|
|
Resmetirom is a liver-directed partial agonist for the thyroid hormone receptor beta (THR-β). Stimulation of THR-β in the liver improves mitochondrial function and lipid metabolism, and increases fatty acid β-oxidation, thereby reducing lipotoxic liver fat, inflammation and liver fibrosis. Resmetirom's liver directed THR-β agonism is particularly relevant in the treatment of MASH and leads to minimal off-target activity on THR-α in tissues such as heart and bone. |
| Document | Type | Information Source | |
|---|---|---|---|
| REZDIFFRA Film-coated tablet | MPI, EU: SmPC | European Medicines Agency (EU) | |
| REZDIFFRA Tablet | MPI, US: SPL/PLR | FDA, National Drug Code (US) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.